Platinum Priority – Prostate CancerEditorial by Bertrand D. Guillonneau and Karim Fizazi on pp. 900–901 of this issueLong-Term Risk of Clinical Progression After Biochemical Recurrence Following Radical Prostatectomy: The Impact of Time from Surgery to Recurrence☆
Introduction
Despite the stage migration that has been noted in prostate cancer (PCa) over the prostate-specific antigen (PSA) era, biochemical recurrence (BCR) continues to be reported in up to 35% of men undergoing radical retropubic prostatectomy (RRP) [1], [2], [3], [4]. Although BCR does not always translate into clinical progression [1], [5], it does precede systemic relapse in the majority of cases, and patients with BCR have been shown to be at increased risk for subsequent metastases and mortality [6]. BCR has also been associated with the use of additional cancer treatments, as approximately a third of men who experience BCR receive a secondary therapy such as external-beam radiation therapy (RT) or androgen-deprivation therapy (ADT) [7].
Defining the natural history of patients with BCR after RRP is therefore relevant for patient counseling, clinical trial enrollment, and the judicious application of secondary therapies. Interestingly, reports to date have documented a relatively heterogeneous natural history of BCR [1], [5], [8], [9]. In addition, as men with PCa are generally >60 yr of age, it has been suggested that competing causes of mortality may obscure the ability of BCR to predict death from PCa [10]. In fact, men have been found to be as likely to die within 15 yr of BCR from competing causes as from PCa [11].
However, whether the outcomes from previous cohorts, which were largely composed of men treated during the pre-PSA and early PSA eras [1], [5], [8], can be extrapolated to the current PCa population has not been established. Moreover, the majority of patients from prior studies [5], [8], in contrast to common clinical practice [6], [7], [12], did not receive salvage therapy until the time of systemic progression. Therefore, the potential impact of secondary treatments on PCa mortality in men with BCR remains to be defined.
A further issue of contention in men with BCR following RRP has been the importance of the time interval from surgery to BCR. Although several series have noted that patients who experience BCR early after RRP are at higher risk for clinical progression and death from PCa [5], [8], [13], others have found that patients who experience BCR earlier after RRP are not at greater risk for subsequent adverse outcomes [1], [9]. Determining the prognostic impact of the disease-free interval after surgery is important, for example, when considering secondary treatments, as a shorter disease-free interval after RRP has been shown to predict receipt of salvage therapy [14]. Here, then, we evaluated long-term clinical outcomes in a large contemporary cohort of patients with BCR after RRP and determined predictors of disease progression and mortality in these men, including the importance of time from RRP to BCR and the impact of secondary cancer therapies.
Section snippets
Methods
After institutional review board approval was obtained, we reviewed our Prostatectomy Registry to identify 14 632 consecutive patients who underwent RRP at the Mayo Clinic between 1990 and 2006 (Table 1). Men who received neoadjuvant (n = 1625) or adjuvant (n = 1921) therapy were excluded from study, as were men who refused release of their records (n = 29) and 639 foreign patients without known follow-up.
Surgical procedures were performed by different surgeons using standardized techniques. The
Results
We identified 2426 men who experienced BCR following RRP and who did not receive neoadjuvant or adjuvant therapy (Table 1). Median age at surgery was 64 yr of age (IQR: 59–69), and median preoperative PSA was 7.9 ng/ml (IQR: 5.2–12.4). Approximately a third of patients had extraprostatic disease at RRP, and half had pathologic Gleason score ≥7 tumors. The fact that only a few men were included with positive lymph nodes (1.4%) reflects our common institutional practice of adjuvant treatment in
Discussion
We report that, at 15 yr following BCR, only 24% of patients had systemic progression, and 16% had died from PCa. In addition, we noted that although early BCR after RRP was associated with adverse clinicopathologic features, the time from surgery to BCR did not independently predict systemic progression or cancer-specific mortality. Instead, pathologic Gleason score, tumor stage, and PSA DT were significantly associated with systemic progression and death from PCa after BCR.
Our findings
Conclusions
Only a minority of men experience systemic progression and death from PCa following BCR after RRP for primarily lymph node–negative disease. Nevertheless, an increased interval from RRP to BCR is not independently associated with diminished risks of progression or mortality. Regardless of the timing of BCR, then, the decision to institute secondary therapies must balance the risk of disease progression based on clinical parameters—in particular, Gleason score, pathologic tumor stage, and PSA
References (29)
- et al.
The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy
J Urol
(2003) - et al.
Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: the 15-year Johns Hopkins experience
Urol Clin North Am
(2001) - et al.
Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3478 consecutive patients: long-term results
J Urol
(2004) - et al.
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy
JAMA
(2005) - et al.
Patterns of secondary cancer treatment for biochemical failure following radical prostatectomy: data from CaPSURE
J Urol
(2004) - et al.
Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function (“trifecta”)
Urology
(2005) - et al.
Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor
J Urol
(2002) - et al.
Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality
J Urol
(2006) - et al.
Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol
(2001) - et al.
PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer
Mayo Clin Proc
(2001)
Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era
J Urol
Impact of patient age at treatment on outcome following radical retropubic prostatectomy for prostate cancer
J Urol
High risk biochemical relapse and the timing of androgen deprivation therapy
J Urol
Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy
J Urol
Cited by (0)
- ☆
Please visit www.eu-acme.org/europeanurology to read and answer questions on-line. The EU-ACME credits will then be attributed automatically.